Johnson & Johnson announces ICOTYDE® (icotrokinra) delivers significant improvement in psoriatic arthritis disease activity among biologic-naive patients with once-daily targeted oral peptide
· prnewswire.com · popularity 19/100 · 0 similar stories today · Medicine & Clinical Health (Health & Life Sciences)
Read the original at prnewswire.com →
Summary
Late-breaking data from Phase 3 investigational study presented at the American College of Rheumatology Convergence show 58% of ICOTYDE-treated patients achieved an ACR20 response and 29% achieved an ACR50 response at Week 16 ICOTYDE is a first-in-class IL-23R targeted oral peptide,...
Found in: PR Newswire. Rating basis: single outlet; outlet tier 2 (unlisted); 1 feeds; feed position 9.